Bluebird Bio (NQ: BLUE )
4.470 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Press Releases about Bluebird Bio
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Topics Artificial Intelligence
Exposures Artificial Intelligence
bluebird bio Sells Second Priority Review Voucher for $95 Million
January 06, 2023
bluebird bio Sells Priority Review Voucher for $102 Million
November 30, 2022
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
October 04, 2022
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLO
From Real Endpoints